These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

633 related articles for article (PubMed ID: 33081391)

  • 1. Facts and Challenges in Immunotherapy for T-Cell Acute Lymphoblastic Leukemia.
    Bayón-Calderón F; Toribio ML; González-García S
    Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33081391
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chimeric Antigen Receptor T-Cells for the Treatment of B-Cell Acute Lymphoblastic Leukemia.
    Tomuleasa C; Fuji S; Berce C; Onaciu A; Chira S; Petrushev B; Micu WT; Moisoiu V; Osan C; Constantinescu C; Pasca S; Jurj A; Pop L; Berindan-Neagoe I; Dima D; Kitano S
    Front Immunol; 2018; 9():239. PubMed ID: 29515572
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acute T-cell lymphoblastic leukemia: chimeric antigen receptor technology may offer a new hope.
    Jing J; Ma Y; Xie Z; Wang B; Chen Y; Chi E; Wang J; Zhang K; Wang Z; Li S
    Front Immunol; 2024; 15():1410519. PubMed ID: 39192970
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 2B4 costimulatory domain enhancing cytotoxic ability of anti-CD5 chimeric antigen receptor engineered natural killer cells against T cell malignancies.
    Xu Y; Liu Q; Zhong M; Wang Z; Chen Z; Zhang Y; Xing H; Tian Z; Tang K; Liao X; Rao Q; Wang M; Wang J
    J Hematol Oncol; 2019 May; 12(1):49. PubMed ID: 31097020
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel generation 1928zT2 CAR T cells induce remission in extramedullary relapse of acute lymphoblastic leukemia.
    Weng J; Lai P; Qin L; Lai Y; Jiang Z; Luo C; Huang X; Wu S; Shao D; Deng C; Huang L; Lu Z; Zhou M; Zeng L; Chen D; Wang Y; Chen X; Geng S; Robert W; Tang Z; He C; Li P; Du X
    J Hematol Oncol; 2018 Feb; 11(1):25. PubMed ID: 29458388
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chimeric antigen receptor T-cell therapy for T-cell acute lymphoblastic leukemia.
    Oh BLZ; Vinanica N; Wong DMH; Campana D
    Haematologica; 2024 Jun; 109(6):1677-1688. PubMed ID: 38832423
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chimeric Antigen Receptor T Cells Targeting NKG2D-Ligands Show Robust Efficacy Against Acute Myeloid Leukemia and T-Cell Acute Lymphoblastic Leukemia.
    Driouk L; Gicobi JK; Kamihara Y; Rutherford K; Dranoff G; Ritz J; Baumeister SHC
    Front Immunol; 2020; 11():580328. PubMed ID: 33384686
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Generation of CAR-T Cells for Cancer Immunotherapy.
    Xu Q; Harto H; Berahovich R; Xu S; Zhou H; Golubovskaya V; Wu L
    Methods Mol Biol; 2019; 1884():349-360. PubMed ID: 30465215
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-CCR9 chimeric antigen receptor T cells for T-cell acute lymphoblastic leukemia.
    Maciocia PM; Wawrzyniecka PA; Maciocia NC; Burley A; Karpanasamy T; Devereaux S; Hoekx M; O'Connor D; Leon T; Rapoz-D'Silva T; Pocock R; Rahman S; Gritti G; Yánez DC; Ross S; Crompton T; Williams O; Lee L; Pule MA; Mansour MR
    Blood; 2022 Jul; 140(1):25-37. PubMed ID: 35507686
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chimeric antigen receptor T cells (CAR-T) for the treatment of T-cell malignancies.
    Cooper ML; DiPersio JF
    Best Pract Res Clin Haematol; 2019 Dec; 32(4):101097. PubMed ID: 31779968
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chimeric antigen-receptor T-cell therapy for hematological malignancies and solid tumors: Clinical data to date, current limitations and perspectives.
    Gauthier J; Yakoub-Agha I
    Curr Res Transl Med; 2017 Sep; 65(3):93-102. PubMed ID: 28988742
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Donor-Derived CD7 Chimeric Antigen Receptor T Cells for T-Cell Acute Lymphoblastic Leukemia: First-in-Human, Phase I Trial.
    Pan J; Tan Y; Wang G; Deng B; Ling Z; Song W; Seery S; Zhang Y; Peng S; Xu J; Duan J; Wang Z; Yu X; Zheng Q; Xu X; Yuan Y; Yan F; Tian Z; Tang K; Zhang J; Chang AH; Feng X
    J Clin Oncol; 2021 Oct; 39(30):3340-3351. PubMed ID: 34324392
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CAR-T Cell Therapy for Acute Lymphoblastic Leukemia: Transforming the Treatment of Relapsed and Refractory Disease.
    Pehlivan KC; Duncan BB; Lee DW
    Curr Hematol Malig Rep; 2018 Oct; 13(5):396-406. PubMed ID: 30120708
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CAR T-cells for relapsed B-cell ALL in adults.
    Gilbert JA
    Lancet Oncol; 2018 Mar; 19(3):e143. PubMed ID: 29429915
    [No Abstract]   [Full Text] [Related]  

  • 15. The efficacy of anti-CD19 chimeric antigen receptor T cells for B-cell malignancies.
    Cao JX; Gao WJ; You J; Wu LH; Liu JL; Wang ZX
    Cytotherapy; 2019 Jul; 21(7):769-781. PubMed ID: 31160157
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Transferrin Receptor-Directed CAR for the Therapy of Hematologic Malignancies.
    Guo Z; Zhang Y; Fu M; Zhao L; Wang Z; Xu Z; Zhu H; Lan X; Shen G; He Y; Lei P
    Front Immunol; 2021; 12():652924. PubMed ID: 33854512
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Myeloid lineage switch following CD7-targeted chimeric antigen receptor T-cell therapy in relapsed/refractory T-cell acute lymphoblastic leukemia.
    Aldoss I; Tizro P; Bedi D; Mangan JK; Clark MC; Spencer D; Song JY; Cherian S; Pillai R; Kim Y; Mahajan N; Gendzekhadze K; James M; Jacobs K; Davidson-Moncada J; Forman SJ; Wang HY; Afkhami M
    Haematologica; 2023 Dec; 108(12):3511-3516. PubMed ID: 37470155
    [No Abstract]   [Full Text] [Related]  

  • 18. Preclinical targeting of aggressive T-cell malignancies using anti-CD5 chimeric antigen receptor.
    Chen KH; Wada M; Pinz KG; Liu H; Lin KW; Jares A; Firor AE; Shuai X; Salman H; Golightly M; Lan F; Senzel L; Leung EL; Jiang X; Ma Y
    Leukemia; 2017 Oct; 31(10):2151-2160. PubMed ID: 28074066
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CAR T cells for infection, autoimmunity and allotransplantation.
    Maldini CR; Ellis GI; Riley JL
    Nat Rev Immunol; 2018 Oct; 18(10):605-616. PubMed ID: 30046149
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preclinical Evaluation of Allogeneic CAR T Cells Targeting BCMA for the Treatment of Multiple Myeloma.
    Sommer C; Boldajipour B; Kuo TC; Bentley T; Sutton J; Chen A; Geng T; Dong H; Galetto R; Valton J; Pertel T; Juillerat A; Gariboldi A; Pascua E; Brown C; Chin SM; Sai T; Ni Y; Duchateau P; Smith J; Rajpal A; Van Blarcom T; Chaparro-Riggers J; Sasu BJ
    Mol Ther; 2019 Jun; 27(6):1126-1138. PubMed ID: 31005597
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.